ArticleMaterials today. Bio2026
ROS-responsive nanoplatform-mediated targeted intranasal delivery of Piezo2 siRNA for the treatment of trigeminal neuralgia.
Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Trigeminal neuralgia (TN) is one of the most severe neuropathic pain conditions, yet current pharmacological treatments are hindered by low bioavailability, systemic toxicity, and drug resistance. The mechanosensitive ion channel Piezo2 has been identified as a key mediator of orofacial mechanical allodynia in TN, making it a highly attractive but as yet clinically untargeted therapeutic target. To address this critical gap, we developed RLPSe nanoparticles, a microenvironment-adaptive nanoplatform composed of a polyvinylamine (PVAm)-L44 copolymer crosslinked via diselenide bonds and conjugated with rabies virus glycoprotein 29 (RVG29). The diselenide bond confers oxidative stress responsiveness, while RVG29 enables specific neuronal targeting. In vitro studies demonstrated that RLPSe nanoparticles exhibited good biocompatibility, oxidative stress responsiveness, and neuronal targeting efficiency; they effectively scavenged intracellular reactive oxygen species and delivered siRNA to knock down Piezo2 expression in neurons. Following intranasal administration
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.